Medicina
Département
Hospital Universitario de Jaén
Jaén, EspañaPublications en collaboration avec des chercheurs de Hospital Universitario de Jaén (71)
2023
-
EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci
International Journal of Antimicrobial Agents, Vol. 62, Núm. 3
-
Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial
Therapeutic Advances in Medical Oncology, Vol. 15
2022
-
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
Cancers, Vol. 14, Núm. 11
-
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
BMC Cancer, Vol. 22, Núm. 1
-
Discovering HIV related information by means of association rules and machine learning
Scientific Reports, Vol. 12, Núm. 1
-
Registro del Grupo NADYA-SENPE de Nutrición Enteral Domiciliaria en España: años 2018 y 2019
Nutricion hospitalaria, Vol. 39, Núm. 1, pp. 223-229
2021
-
Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the thoracic tumor registry
PLoS ONE, Vol. 16, Núm. 6 June
-
Neurological presentations of COVID-19: Findings from the Spanish Society of Neurology neuroCOVID-19 registry
Journal of the Neurological Sciences, Vol. 423
-
Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 6, pp. 413-420
-
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
BMC Cancer, Vol. 21, Núm. 1
-
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens
Scientific Reports, Vol. 11, Núm. 1
-
Real-life use of ramucirumab in gastric cancer in Spain: The RAMIS study
Future Oncology, Vol. 17, Núm. 14, pp. 1777-1791
2020
-
ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort
Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 140-148
-
Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer
European Urology
-
Consensus Document on the Diagnosis and Treatment of Chronic Bronchial Infection in Chronic Obstructive Pulmonary Disease
Archivos de Bronconeumologia, Vol. 56, Núm. 10, pp. 651-664
-
Home and Ambulatory Artificial Nutrition (NADYA) group report. Home parenteral nutrition in Spain, 2018
Nutricion Hospitalaria, Vol. 37, Núm. 2, pp. 403-407
-
Serum phospholipids fatty acids and breast cancer risk by pathological subtype
Nutrients, Vol. 12, Núm. 10, pp. 1-18
-
Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation
Cancer Epidemiology, Vol. 67
2019
-
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients
Leukemia Research, Vol. 76, pp. 1-10
-
DALBACEN cohort: Dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
Annals of Clinical Microbiology and Antimicrobials, Vol. 18, Núm. 1